SNPX logo

Synaptogenix, Inc. Common Stock


SNPX: Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.


Show SNPX Financials

Consumer Interest
SEC Filings

Recent trades of SNPX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by SNPX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Pkc-activating compounds for the treatment of neurodegenerative diseases Jul. 19, 2022
  • Patent Title: Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases Mar. 15, 2022
  • Patent Title: Methods for inducing synaptogenesis with synaptic growth factor activating compounds Jun. 29, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of SNPX in WallStreetBets Daily Discussion


Recent insights relating to SNPX

CNBC Recommendations

Recent picks made for SNPX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SNPX

Corporate Flights

Flights by private jets registered to SNPX